OptiBiotix Health PLC (AIM:OPTI, OTCQB:OPTBF), the AIM-listed life sciences company developing gut microbiome products and healthy sugar substitutes, saw its shares jump 13.5% to 5.68p after announcing plans to demonstrate its SweetBiotix products to shareholders at a London event in...

OptiBiotix Health PLC (AIM:OPTI, OTCQB:OPTBF) shares rose 10% to 6.42p on Tuesday after the life sciences group said it had no current intention to sell its 5.64% stake in SkinBioTherapeutics following market uncertainty caused by recent statements from the skincare company. OptiBiotix also...

Solvonis Therapeutics PLC (LSE:SVNS, FRA:J4I) says new preclinical data shows its lead drug matches fluoxetine (Prozac) in depression models. The drug targets serotonin and dopamine, aiming to help patients who don’t fully respond to current antidepressants. hVIVO PLC (AIM:HVO) expects full-year revenue around £46.7 million, with margins beating expectations after a strong Q4. The company says recent acquisitions mean it’s now a full-service early-stage drug development group. OptiBiotix Health PLC (AIM:OPTI, OTCQB:OPTBF) is seeing strong demand for its SlimBiome weight management ingredient, especially in the US. Management says growth is driven by consumers looking for alternatives to drugs like Ozempic. Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) has secured a €4 million non-dilutive grant to push key programmes. Focus is on its MASH gene therapy and a first-of-its-kind longevity study in ageing dogs. Valereum PLC (AQSE:VLRM, FRA:6TJ) has added $200 million to its balance sheet after completing a major transaction. The company says several tokenisation and markets infrastructure deals are moving closer to launch. Tooru PLC (AIM:TOO, FRA:73N) says momentum is building after its AIM listing and business consolidation. Brands like OAF are gaining traction in Tesco, with management eyeing wider retail and overseas expansion. Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.

OptiBiotix Health PLC (AIM:OPTI, OTCQB:OPTBF) chief executive Stephen O’Hara talked with Proactive's Stephen Gunnion about the company’s growing exposure to the weight management and gut health markets, highlighting rising global demand for its SlimBiome product and the strategic importance of its US expansion. O’Hara explained that OptiBiotix Health is a microbiome company focused on developing products that address unmet healthcare needs rather than selling science alone. One of the company’s flagship products, SlimBiome, is a patented ingredient designed to reduce hunger and food cravings, helping consumers eat less and manage weight more effectively. He noted that SlimBiome has won multiple awards and is already sold globally, with a recent US launch through Hydroxycut Hunger Control, an extension of America’s leading weight management brand. Discussing recent commercial momentum, O’Hara pointed to a substantial 24-metric-tonne order from Meelung Trading in Taiwan, which he said reflects accelerating demand across Asia. He linked this growth to increased interest in alternatives to GLP-1 drugs such as Ozempic and semaglutide, explaining that some consumers prefer not to take drugs, cannot afford them, or are seeking weight maintenance solutions after stopping medication. As O’Hara put it, “this is a big market… worth $1.2 billion in 2024 and growing about 17% per year.” The interview also covered OptiBiotix Health’s broader product platform, including WellBiome for gut health, SweetBiotix as a sweet fibre, and longer-term microbiome modulators. O’Hara additionally outlined the rationale for the company joining the OTCQB market last year, which increases accessibility and liquidity for US investors at a time of growing awareness of the microbiome sector in the US. For more insights from company leaders, visit Proactive’s YouTube channel, and don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss future updates. #OptiBiotix #OptiBiotixHealth #SlimBiome #GLP1 #WeightManagement #GutHealth #Microbiome #HealthSupplements #AntiObesity #AIMStocks #OTCQB #USExpansion #InvestorInterview #ProactiveInvestors